|
PMDA-USP Workshop - Nitrosamines Track
|
|
2
|
582
|
September 17, 2024
|
|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1912
|
September 5, 2024
|
|
📅 FDA - CRCG Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products -Event
|
|
1
|
1053
|
August 14, 2024
|
|
IPEC Webinar on the role of excipients in determine N-nitrosamine risks
|
|
3
|
517
|
July 24, 2024
|
|
Classification of potentially mutagenic impurities under the ICH M7 guideline -Event
|
|
0
|
434
|
July 23, 2024
|
|
Nitrosamine in vivo mutagenicity workshop
|
|
10
|
896
|
July 22, 2024
|
|
Nitrosamine impurities in medicines (presented at the ARCS Annual Conference 2024)
|
|
12
|
1338
|
July 17, 2024
|
|
USP India - Nitrosamines panel discussion at USP Science Conclave
|
|
0
|
380
|
July 10, 2024
|
|
EPR Podcast Ep 26 – Navigating Nitrosamine Impurities
|
|
0
|
393
|
June 26, 2024
|
|
Predicting Nitrosamine Formation in the Solid State
|
|
3
|
868
|
June 24, 2024
|
|
Common Template for initial assessment of Nitrosamine impurities
|
|
0
|
696
|
June 20, 2024
|
|
Insights from the Lhasa Limited and IPEC Europe Nitrites collaborative meeting
|
|
1
|
580
|
June 16, 2024
|
|
🇲🇽 Conferencia USP Nitrosaminas en México presencial 21-Marzo
|
|
4
|
811
|
May 27, 2024
|
|
Managing the complexities of NDSRI method development: The N-nitroso propranolol case story
|
|
0
|
566
|
May 14, 2024
|
|
Using the Carcinogenicity Potency Categorization Algorithm to Predict N-Nitrosamine Carcinogenicity -Webinar
|
|
0
|
388
|
May 13, 2024
|
|
🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024
|
|
5
|
1557
|
April 14, 2024
|
|
📅 Ascorbic Acid And Alpha-Tocopherol As Nitrite Scavengers - An Elegant And Simple Solution To Mitigate Nitrosamines In Drug Products -Event
|
|
0
|
952
|
April 5, 2024
|
|
USP User Forum in 🇨🇦 Toronto
|
|
0
|
257
|
March 12, 2024
|
|
Read-across Masterclass: How To Facilitate Your Acceptable Intake Limit Setting For Nitrosamines
|
|
0
|
397
|
March 7, 2024
|
|
HESI Open call to Q(SAR) and QM working group
|
|
3
|
853
|
February 20, 2024
|
|
TALK SERIES: Navigating Nitrosamine and NDSRIs regulations with Dr. Reddy´s Laboratories
|
|
1
|
804
|
February 11, 2024
|
|
Exploring the CPCA Framework: Defining Acceptable Intake for NDSRIs -Event
|
|
2
|
962
|
January 10, 2024
|
|
Upcoming and recorded Lhasa webinars
|
|
3
|
932
|
December 21, 2023
|
|
Nitrosamine Impurities Deadline: Are Your Products Compliant?
|
|
6
|
773
|
December 6, 2023
|
|
8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit
|
|
1
|
1089
|
December 1, 2023
|
|
10º encontro Farmacopeia Brasileira
|
|
0
|
541
|
November 30, 2023
|
|
Free Webinar: Nitrosamines in Drug Products
|
|
12
|
2029
|
November 16, 2023
|
|
Nitrosamine Risk Reduction In Pharmaceutical Formulations Webinar
|
|
1
|
909
|
November 6, 2023
|
|
USP, EDQM, JP, IPC through Pharmacopeial Discussion Group on Nitrosamines
|
|
2
|
588
|
November 2, 2023
|
|
FDA - Pharmaceutical Quality Symposium
|
|
1
|
859
|
November 1, 2023
|